1-methyl-3,6-dihydro-2H-pyridin-4-amine | 6629-90-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-methyl-3,6-dihydro-2H-pyridin-4-amine
• CAS: 6629-90-9
• 化学式: C₆H₁₂N₂
• 分子量: 112.17
• InChiKey: MXTMSSBJSSPHKN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION<br/>[FR] MÉTHODES ET COMPOSÉS DESTINÉS À LA RESTAURATION D'UNE FONCTION DE MUTANTS DE P53
  申请人：PMV PHARMACEUTICALS INC

  公开号：WO2021262684A1

  公开（公告）日：2021-12-30

  Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

  癌基因和肿瘤抑制基因的突变促成了癌症的发展和进展。本公开披露描述了一种恢复p53突变体DNA结合亲和力的化合物和方法。本公开披露的化合物可以结合突变型p53，并恢复p53突变体结合DNA并激活参与肿瘤抑制的下游效应子的能力。披露的化合物可用于减少含有p53突变的癌症的进展。
• [EN] SUBSTITUTED PYRROLOPYRIDINE-DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRROLOPYRIDINE SUBSTITUÉS
  申请人：BAYER PHARMA AG

  公开号：WO2019016071A1

  公开（公告）日：2019-01-24

  The present invention relates to protein-inhibitory substituted pyrrolopyridine derivatives of formula (I), in which A, X, R1, R2a, R2b, R3a, R3b, R4a and R4b are as defined herein, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, repectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients. The present invention further relates to the use, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control.

  本发明涉及式(I)的蛋白抑制取代吡咯吡啶衍生物，其中A、X、R1、R2a、R2b、R3a、R3b、R4a和R4b如本文所定义，以及包含根据本发明的化合物的药物组合物和药物组合物，以及创新化合物的预防和治疗用途，分别用于制造用于治疗或预防疾病的药物组合物，特别是用于肿瘤性疾病、癌症或与MAP4K1信号异常相关的其他疾病的治疗或预防，作为单一药剂或与其他活性成分组合使用。本发明还涉及用途，分别用于制造用于治疗或预防良性增生、动脉粥样硬化疾病、败血症、自身免疫性疾病、血管疾病、病毒感染、神经退行性疾病、炎症性疾病、动脉粥样硬化疾病和男性生育控制的蛋白抑制剂的药物组合物。
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：AC IMMUNE SA

  公开号：WO2022078971A1

  公开（公告）日：2022-04-21

  The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of diseases, disorders and or abnormality associated with misfolding of Tau protein and/or pathological aggregation of Tau (Tubulin associated unit) protein including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD). The present invention also relates to processes for the preparation of said compounds, pharmaceutical compositions comprising said compounds, methods using said compounds, combinations comprising said compounds, medicaments containing them, and their uses in diseases, disorders and/or abnormalities associated with misfolding of Tau protein and/or pathological aggregation of Tau (Tubulin associated unit) protein.

  本发明涉及一类新化合物，可用于治疗、缓解或预防一组与Tau蛋白误折叠和/或Tau（微管相关单元）蛋白的病理聚集有关的疾病、疾病和/或异常，包括但不限于神经纤维缠结（NFT），如阿尔茨海默病（AD）。本发明还涉及制备所述化合物的方法，包括所述化合物的制药组合物，使用所述化合物的方法，包括所述化合物的组合物，含有它们的药物以及它们在与Tau蛋白误折叠和/或Tau（微管相关单元）蛋白的病理聚集有关的疾病、疾病和/或异常中的用途。
• PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF
  申请人：Merck Patent GmbH

  公开号：EP3013832B1

  公开（公告）日：2020-11-04
• [EN] [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS PROTOZOAN PROTEASOME INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES SUCH AS LEISHMANIASIS<br/>[FR] DÉRIVÉS DE [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE UTILISÉS COMME INHIBITEURS DU PROTÉASOME DES PROTOZOAIRES POUR LE TRAITEMENT DE MALADIES PARASITAIRES COMME LA LEISHMANIOSE
  申请人：IRM LLC

  公开号：WO2015095477A1

  公开（公告）日：2015-06-25

  The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.